Patent classifications
C07D295/03
Corrosion inhibition
A corrosion inhibiting compound with a general structure A-B or A-X-B for inhibition of corrosion of steel in acidic solution. A comprises a heterocyclic ring system having a plurality of cyclic Carbon atoms and at least one cyclic Nitrogen atom, wherein the at least one cyclic Nitrogen atom is neutral under neutral conditions and protonatable under acidic conditions. B comprises at least two unsaturated Carbon atoms. B may comprise a ring system or a polymerisable group.
Corrosion inhibition
A corrosion inhibiting compound with a general structure A-B or A-X-B for inhibition of corrosion of steel in acidic solution. A comprises a heterocyclic ring system having a plurality of cyclic Carbon atoms and at least one cyclic Nitrogen atom, wherein the at least one cyclic Nitrogen atom is neutral under neutral conditions and protonatable under acidic conditions. B comprises at least two unsaturated Carbon atoms. B may comprise a ring system or a polymerisable group.
POLYOXOMETALATE COMPOUND AND METHOD FOR PRODUCING SAME, SINTERED BODY OF POLYOXOMETALATE COMPOUND, AND REACTION CATALYST
Disclosed is a polyoxometalate compound including a metal-substituted polyoxometalate. The metal-substituted polyoxometalate includes a polyoxometalate having defect sites, a substituting metal atom introduced into the defect sites, and an organic ligand. The substituting metal atom is divalent platinum or palladium. The organic ligand may be a bidentate ligand having an aliphatic heterocycle containing two nitrogen atoms coordinately bonded to the substituting metal atom. One substituting metal atom is introduced into one defect site.
PROCESS FOR THE PREPARATION OF DIPHENYLPYRAZINE DERIVATIVES
The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.
PROCESS FOR THE PREPARATION OF DIPHENYLPYRAZINE DERIVATIVES
The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.
Modified Conjugated Diene-Based Polymer and Rubber Composition Including the Same
A modified conjugated diene-based polymer and a rubber composition including a modified conjugated diene-based polymer are disclosed herein. In some embodiments, a modified conjugated diene-based polymer includes a functional group derived from a modification initiator at one terminal and a functional group derived from a modifier represented by the Formula 2 or Formula 3 at the other terminal, wherein the modified conjugated diene-based polymer having a unimodal molecular weight distribution, and a polydispersity index of 1.0 to less than 1.7. The modified conjugated diene-based polymer prepared by continuous polymerization and having remarkable processability, narrow molecular weight distribution and excellent physical properties.
Modified Conjugated Diene-Based Polymer and Rubber Composition Including the Same
A modified conjugated diene-based polymer and a rubber composition including a modified conjugated diene-based polymer are disclosed herein. In some embodiments, a modified conjugated diene-based polymer includes a functional group derived from a modification initiator at one terminal and a functional group derived from a modifier represented by the Formula 2 or Formula 3 at the other terminal, wherein the modified conjugated diene-based polymer having a unimodal molecular weight distribution, and a polydispersity index of 1.0 to less than 1.7. The modified conjugated diene-based polymer prepared by continuous polymerization and having remarkable processability, narrow molecular weight distribution and excellent physical properties.
Process for the preparation of diphenylpyrazine derivatives
The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.
Process for the preparation of diphenylpyrazine derivatives
The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.
NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS
Compounds that inhibit p38 MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.